ExodusPoint Capital Management LP Invests $428,000 in Annexon, Inc. (NASDAQ:ANNX)

ExodusPoint Capital Management LP purchased a new position in shares of Annexon, Inc. (NASDAQ:ANNX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 83,437 shares of the company’s stock, valued at approximately $428,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. E Fund Management Co. Ltd. raised its position in Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after buying an additional 4,086 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Annexon during the fourth quarter worth about $98,000. Arizona State Retirement System acquired a new stake in Annexon in the fourth quarter valued at about $102,000. Teacher Retirement System of Texas purchased a new stake in Annexon in the 4th quarter valued at approximately $106,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Annexon during the 4th quarter worth approximately $116,000.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ANNX. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of Annexon in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Annexon in a report on Tuesday, December 17th.

Annexon Price Performance

Shares of NASDAQ:ANNX opened at $1.49 on Friday. Annexon, Inc. has a 12 month low of $1.29 and a 12 month high of $7.85. The firm has a market capitalization of $163.47 million, a price-to-earnings ratio of -1.42 and a beta of 1.24. The business’s 50 day simple moving average is $2.48 and its 200-day simple moving average is $4.56.

Annexon (NASDAQ:ANNX) last posted its earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, equities analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current year.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.